Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BLFS vs FEMY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BLFS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)
BLFS Overall Winner
6-Pillar Tally: BLFS 6 – 0 FEMY
Matrix Metrics: BLFS 9 – 1 FEMY
As of Nov 16, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLFS carries a Unified Composite Score of 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin).
- Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -763.9% operating margin) and revenue trajectory (+21.5% vs. -18.9% YoY).
- Technical & Structure Timing Caution: BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BLFS vs FEMY
BLFS
Head-to-Head Winner
BioLife Solutions Inc.
$38.61
+3.51% 1D
Market Cap
$1.8B
TTM Revenue
$107M
Forward P/E
117.0x
Beta / 30D Vol
1.05β · 31% Vol
Unified Composite Score
46.0
HOLD
Tech 27.0
Fund 46.0
Flow 59.0
Mom 56.0
Weinstein Technical Phase
Markup · Hold / add on dips
FEMY
Femasys Inc. Common Stock
$1.28
-9.86% 1D
Market Cap
$11.9M
TTM Revenue
$2.3M
Forward P/E
N/M
Beta / 30D Vol
4.01β · 72% Vol
Unified Composite Score
52.6
HOLD
Tech 61.0
Fund 62.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (BLFS 6 – 0 FEMY)
1. Valuation Multiples
BLFS
Forward P/E
117.0x
N/M
Trailing P/E
37.3x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
17.0x
4.9x
2. Growth & Scale
BLFS
Revenue Growth (YoY)
+21.5%
-18.9%
Earnings Growth (YoY)
-13.9%
+0.0%
TTM Revenue (USD)
$107M
$2.3M
Market Cap
$1.8B
$11.9M
3. Profitability & Quality
BLFS
Gross Margin
63.6%
60.9%
Operating Margin
6.0%
-763.9%
Net Profit Margin
54.4%
0.0%
Return on Equity (ROE)
12.8%
-425.0%
4. Balance Sheet & Cash Flow
BLFS
Cash Generation (TTM)
-$2.2M
-$19M
Cash Flow Margin
-2.1%
N/A
Net Cash / Leverage
$8.3M Net Cash
-$658,045 Net Debt (0.65x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BLFS
Options Structure Phase
BREAKOUT
UNCLASSIFIED
Current IV / %ile
40.1% (6th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
BLFS
OpEx & R&D Intensity
57.6% of Rev ($61M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Instruments & Supplies Operator
Medical Instruments & Supplies Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BLFS (9) vs FEMY (1)| Institutional Metric | BLFS | FEMY | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.8B | $11.9M | BLFS | |
| Trailing P/E Ratio | 37.3x | N/M | BLFS | |
| Forward P/E Ratio | 117.0x | N/M | BLFS | |
| Revenue Growth (YoY) | +21.5% | -18.9% | BLFS | |
| Operating Margin (TTM) | 6.0% | -763.9% | BLFS | |
| Net Profit Margin | 54.4% | 0.0% | BLFS | |
| Return on Equity (ROE) | 12.8% | -425.0% | BLFS | |
| 52-Week Range Position | 95% ($18–$40) | 17% ($0–$6) | BLFS | |
| Beta / 30D Volatility | 1.05β · 31% Vol | 4.01β · 72% Vol | BLFS | |
| Unified Institutional Score | 46.0 / 100 (HOLD) | 52.6 / 100 (HOLD) | FEMY | |
| Trailing 12M Revenue (USD) | $107M | $2.3M | Scale | |
| Gross Profit Margin (TTM) | 63.6% | 60.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 17.0x EV/Rev | N/M PEG · 4.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$2.2M ($8.3M Net Cash) | -$19M (-$658,045 Net Debt (0.65x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BLFS +42.66 pp
3M Horizon
BLFS +86.04 pp
6M Horizon
FEMY +269.74 pp
1Y Horizon
FEMY +90.68 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BLFS Revenue | FEMY Revenue | BLFS Op. Margin | FEMY Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $20M | N/A | 18.5% | N/A | BLFS |
| FY2019 | $30M | N/A | -0.8% | N/A | BLFS |
| FY2020 | $50M | $0M | -13.0% | -668.0% | BLFS |
| FY2021 | $120M | $0M | -29.5% | -706.7% | BLFS |
| FY2022 | $80M | $0M | -7.8% | -961.7% | BLFS |
| FY2023 | $70M | $0M | -25.3% | -1353.4% | BLFS |
| FY2024 | $70M | $0M | -6.0% | -1091.8% | BLFS |
| FY2025 | $100M | $0M | -17.3% | -767.0% | BLFS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BLFS
BREAKOUT
Current IV
40.1%
IV Percentile
6th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact BLFS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
FEMY
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BLFS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
57.6% of Rev ($61M)
90D Engineering Disclosures
0 Published
FEMY Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ BLFS vs FEMY Key Questions & Quantitative Answers
As of Nov 16, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLFS carries a Unified Composite Score of 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -763.9% operating margin) and revenue trajectory (+21.5% vs. -18.9% YoY). Technical & Structure Timing Caution: BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BLFS leads the Growth & Scale pillar: BLFS posts +21.5% YoY revenue growth and -13.9% YoY earnings growth on $107M TTM revenue (63.6% gross margin, 6.0% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BLFS cumulative revenue shifted +400.0% while FEMY shifted N/A. In operating R&D and SG&A reinvestment, BLFS deploys 57.6% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.
BLFS screens cheaper on headline valuation multiples. BLFS trades at 117.0x Forward P/E, 37.3x Trailing P/E, N/M PEG, and 17.0x EV/Revenue (-2.1% FCF margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLFS (12.8% ROE) versus FEMY (-425.0% ROE) capital efficiency.
In options market volatility and institutional positioning, BLFS carries 40.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 31% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
FEMY vs BLFS · Reverse Pair
BLFS vs CYRX
· Sector Peer
BLFS vs AXGN
· Sector Peer
BLFS vs VCEL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking